Assuntos
Falso Aneurisma/diagnóstico , Toxinas Botulínicas/efeitos adversos , Neurotoxinas/efeitos adversos , Artérias Temporais/efeitos dos fármacos , Falso Aneurisma/induzido quimicamente , Falso Aneurisma/cirurgia , Toxinas Botulínicas/administração & dosagem , Feminino , Humanos , Pessoa de Meia-Idade , Neurotoxinas/administração & dosagem , Artérias Temporais/diagnóstico por imagem , Artérias Temporais/cirurgiaRESUMO
Importance: Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) are structurally and functionally related, yet different in their migraine-inducing properties. It remains unclear whether the lack of migraine induction can be attributed to the only transient vasodilatory response after a 20-minute infusion of VIP. Objective: To determine whether a 2-hour infusion of VIP would provoke migraine attacks. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled, crossover study was conducted between May and September 2020 at the Danish Headache Center in Copenhagen, Denmark. Patients were eligible for inclusion if they were ages 18 to 40 years, weighed between 50 and 90 kg, had a diagnosis of migraine without aura as defined by the International Classification of Headache Disorders, and had a migraine frequency of 1 to 6 attacks per month. Interventions: Patients were randomly allocated to receive a 2-hour infusion of VIP or placebo on 2 different days. Main Outcomes and Measures: The primary end point was the difference in incidence of experimentally induced migraine attacks during the observational period (0-12 hours) between VIP and placebo. Results: Twenty-one patients (17 [81%] women and 4 [19%] men; mean [range] age, 25.9 [19-40] years) were recruited in the study. Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after VIP compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001). The VIP-induced migraine attacks mimicked patients' spontaneous attacks. The area under the curve (AUC) of headache intensity scores (0-12 hours), as well as the AUC of the superficial temporal artery diameter (0-180 minute) were significantly greater after VIP compared with placebo (AUC0-12h, P = .003; AUC0-180min, P < .001). Conclusions and Relevance: A 2-hour infusion of VIP caused migraine attacks, suggesting an important role of VIP in migraine pathophysiology. VIP and its receptors could be potential targets for novel migraine drugs. Trial Registration: ClinicalTrials.gov Identifier: NCT04260035.
Assuntos
Transtornos de Enxaqueca/induzido quimicamente , Transtornos de Enxaqueca/epidemiologia , Peptídeo Intestinal Vasoativo/efeitos adversos , Vasodilatadores/efeitos adversos , Adolescente , Adulto , Área Sob a Curva , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Incidência , Infusões Intravenosas , Masculino , Artérias Temporais/efeitos dos fármacos , Peptídeo Intestinal Vasoativo/administração & dosagem , Vasodilatadores/administração & dosagem , Adulto JovemRESUMO
Identifying comorbidities in polymyalgia rheumatica/giant cell arteritis (PMR/GCA) is crucial for patients' outcomes. The present study aimed to evaluate the impact of the inflammatory process and glucocorticoid treatment on aortic arterial stiffness and body composition in PMR/GCA. 77 patients with newly diagnosed PMR/GCA were treated with oral glucocorticoids and followed for 40 weeks. Aortic pulse wave velocity (PWV) was measured at baseline and during the follow-up period and compared to the results of temporal artery biopsy (TAB) and 18F-FDG PET/CT. Body composition was assessed by total body DXA at baseline and the end of the study. Of 77 patients (49 (63.6%) female, mean of age: (71.8 ± 8.0)), 64 (83.1%) had pure PMR, 10 (13.0%) concomitant PMR and GCA, and 3 (3.9%) pure GCA. Compared to baseline values, aortic PWV was initially decreased at week 16 (p = 0.010) and remained lower than baseline at week 28 (p = 0.002) and week 40 (p < 0.001), with no association with results of TAB and 18F-FDG PET/CT. Aortic PWV was significantly associated with age, male gender, left systolic and diastolic blood pressure, right diastolic blood pressure, and CRP. Total bone mineral content (BMC) was decreased in both genders (p < 0.001), while fat mass (FM) was significantly increased (p < 0.001). However, lean body mass did not significantly change during the study. Changes in FM were correlated with cumulative prednisolone dose (rho: 0.26, p = 0.031). Glucocorticoid treatment of patients with PMR/GCA had several prognostic impacts. Arterial stiffness was decreased due either to the treatment or a reduction in the inflammatory load. Additionally, treatment led to changes in body composition, including a decrease in BMC and FM excess.
Assuntos
Aorta/efeitos dos fármacos , Arterite de Células Gigantes/tratamento farmacológico , Glucocorticoides/uso terapêutico , Polimialgia Reumática/tratamento farmacológico , Prednisolona/uso terapêutico , Tecido Adiposo Branco/diagnóstico por imagem , Tecido Adiposo Branco/efeitos dos fármacos , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Aorta/metabolismo , Biópsia , Pressão Sanguínea/efeitos dos fármacos , Composição Corporal/efeitos dos fármacos , Densidade Óssea/efeitos dos fármacos , Proteína C-Reativa/metabolismo , Feminino , Fluordesoxiglucose F18/metabolismo , Arterite de Células Gigantes/sangue , Arterite de Células Gigantes/diagnóstico por imagem , Arterite de Células Gigantes/patologia , Humanos , Estudos Longitudinais , Masculino , Polimialgia Reumática/sangue , Polimialgia Reumática/diagnóstico por imagem , Polimialgia Reumática/patologia , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Prognóstico , Análise de Onda de Pulso , Fatores Sexuais , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/metabolismo , Rigidez Vascular/efeitos dos fármacosRESUMO
BACKGROUND: In recent years, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) have gained special interest in headache science. VIP and PACAPs (two isoforms, PACAP27 and PACAP38) are related in structure and function, as are their receptors, but they show differences in vasodilating- and headache-inducing properties. Intravenous infusion of PACAP27 or PACAP38, but not VIP, induces a long-lasting dilation of cranial arteries and delayed headache. The relationship between the long-lasting cranial vasodilation and headache development is not fully clarified. METHODS: In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo. Primary endpoints were the differences in area under the curve for the superficial temporal artery diameter and headache intensity scores, as well as in headache incidence, between VIP and placebo. RESULTS: The superficial temporal artery diameter was significantly larger on the VIP day compared to placebo (p < 0.001) and the dilation lasted for more than 2 h. The incidence of headache was higher (p = 0.003) on the VIP day compared to the placebo day. The difference in headache intensity scores was more evident in the post-infusion period (120-200 min, p = 0.034) and in the post-hospital phase (4-12 h, p = 0.025). Cranial parasympathetic activity, measured through the production of tears, was higher during VIP compared to placebo (p = 0.033). CONCLUSION: Continuous intravenous infusion of VIP over 2 h induced a long-lasting cranial vasodilation, activation of the cranial parasympathetic system, and delayed mild headaches in healthy volunteers.Trial Registration: The study is registered at ClinicalTrials.gov (NCT03989817).
Assuntos
Cefaleia/induzido quimicamente , Artérias Temporais/efeitos dos fármacos , Peptídeo Intestinal Vasoativo/farmacologia , Vasodilatadores/farmacologia , Adulto , Estudos Cross-Over , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Infusões Intravenosas , Masculino , Vasodilatação/efeitos dos fármacosAssuntos
Biópsia/métodos , Formaldeído/farmacologia , Arterite de Células Gigantes/diagnóstico , Artérias Temporais/patologia , Fixação de Tecidos/métodos , Idoso , Idoso de 80 Anos ou mais , Feminino , Fixadores/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Artérias Temporais/efeitos dos fármacosRESUMO
OBJECTIVE: In the present study, we used a two-kidney-two-clip (2k2c) stroke-prone renovascular hypertension rat model (RHRSP) to investigate the protective effects of ligustrazine (TMP) on cerebral arteries and to examine PI3K/Akt pathway behavior under this protection. METHODS: The cerebral artery remodeling was induced by 2k2c-induced renovascular hypertension. Brain basilar artery tissues were isolated and their histological changes were detected through H&E and EVG staining, α-SMA IHC staining, and transmission electron microscopy at four, eight, and twelve weeks after 2k2c surgery, both with and without TMP treatment. Meanwhile, the ET-1, Ang II, and NO levels in basilar arteries and plasma were determined. Furthermore, the PTEN expression and the activation of PI3K/Akt in basilar artery tissues were detected through IHC and Western Blot. In addition, the primary basilar artery smooth muscle cells (BASMCs) were cultured and TMP protection of BASMCs stimulated with ET-1/Ang II in the presence or absence of insulin-like growth factor 1 (IGF-1) was determined. RESULTS: TMP attenuated basilar artery remodeling, decreased ET-1 and Ang II levels and increased NO level in basilar arteries and plasma of RHRSP rats. Moreover, TMP reduced BASMCs proliferation upon ET-1/Ang II stimulation. We also found that TMP could effectively suppress the activation of PI3K/Akt in 2k2c-RHRSP rat basilar artery and ET-1/Ang II stimulated BASMCs. Most importantly, IGF-1, as an activator of PI3K/Akt, could damage the protective effect of TMP. CONCLUSIONS: TMP exerts its protective effects and prevents basilar artery remodeling in RHRSP rats at least partly through the inhibition of PI3K/Akt pathway.
Assuntos
Hipertensão Renovascular/tratamento farmacológico , Fosfatidilinositol 3-Quinase/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Pirazinas/farmacologia , Artérias Temporais/efeitos dos fármacos , Remodelação Vascular/efeitos dos fármacos , Angiotensina II/metabolismo , Animais , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Modelos Animais de Doenças , Endotelina-1/metabolismo , Hipertensão Renovascular/enzimologia , Hipertensão Renovascular/patologia , Hipertensão Renovascular/fisiopatologia , Ligadura , Masculino , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/enzimologia , Músculo Liso Vascular/fisiopatologia , Músculo Liso Vascular/ultraestrutura , Miócitos de Músculo Liso/efeitos dos fármacos , Miócitos de Músculo Liso/enzimologia , Miócitos de Músculo Liso/patologia , Óxido Nítrico/metabolismo , Ratos Sprague-Dawley , Artéria Renal/cirurgia , Transdução de Sinais , Artérias Temporais/enzimologia , Artérias Temporais/fisiopatologia , Artérias Temporais/ultraestruturaRESUMO
OBJECTIVE: This study sought to determine the effect of temporal artery biopsy (TAB) postfixation length, laterality, age, and prior prednisone exposure on TAB positivity utilizing the Veterans Health Administration national database. METHODS: Subjects with procedure code for TAB between 1999 and 2017 were queried, and pathology reports were reviewed manually. Demographic, laboratory, and prescription data were extracted. Multivariate analyses and logistic regression were run using Stata, version 13.0. RESULTS: A total of 3,057 pathology reports were reviewed; 306 biopsies (10%) were designated positive. The likelihood of a positive TAB significantly correlated with TAB postfixation length of >3.0 cm (odds ratio [OR] 1.58 [95% confidence interval (95% CI) 1.06, 2.36], P < 0.05) as well as with bilateral biopsy in 1 sitting (OR 1.83 [95% CI 1.29, 2.59], P < 0.01). Positive TAB also significantly correlated with age >71 years. Prednisone administration up to and beyond 42 days prior to TAB did not influence TAB result. CONCLUSION: This retrospective study examined predictors of TAB positivity and utilized national data collected on US veterans over the span of 18 years. The results suggest consideration of pursuing initial bilateral TAB or achieving a TAB postfixation length of at least 3 cm to improve yield. The results also agree with prior studies showing that pre-TAB steroid exposure does not appear to affect yield even up to and beyond 42 days prior to biopsy.
Assuntos
Arterite de Células Gigantes/patologia , Artérias Temporais/patologia , Serviços de Saúde para Veteranos Militares , Idoso , Idoso de 80 Anos ou mais , Biópsia , Bases de Dados Factuais , Feminino , Arterite de Células Gigantes/tratamento farmacológico , Glucocorticoides/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prednisona/uso terapêutico , Estudos Retrospectivos , Artérias Temporais/efeitos dos fármacos , Fatores de Tempo , Estados Unidos , United States Department of Veterans AffairsRESUMO
Pituitary adenylate cyclase-activating polypeptide (PACAP) has emerged as an important signaling peptide in migraine pathogenesis. Recently, we have shown that the less-abundant PACAP isoform, PACAP27, induced migraine and headache in patients equipotently to PACAP38. The present study examined the effect of PACAP27 on cerebral hemodynamics in healthy volunteers using high resolution magnetic resonance angiography (MRA). Eighteen healthy volunteers received infusion of PACAP27 (10â¯pmol/kg/min) or placebo over 20â¯min and were scanned repeatedly in fixed intervals for 5â¯h in a double-blind, randomized, placebo-controlled study. The circumference of extra-intracerebral arteries was measured and compared with PACAP38 data. We found significant dilation of middle meningeal artery (MMA) (pâ¯=â¯0.019), superficial temporal artery (pâ¯=â¯0.001) and external carotid artery (pâ¯=â¯0.039) after PACAP27 infusion compared to placebo. Whereas the middle cerebral artery (MCA) (pâ¯=â¯0.011) and internal carotid artery (ICA) (pICAcervicalâ¯=â¯0.015, pICAcerebralâ¯=â¯0.019) were constricted. No effects on basilar artery (pâ¯=â¯0.708) and cavernous portion of ICA were found. Post hoc analyses revealed significant larger area under the curve for MMA after PACAP38 compared to PACAP27 (pâ¯=â¯0.033). We also found that PACAP27 induced headache in nine out of twelve (75%) volunteers and one (17%) after placebo. In conclusion, PACAP27 induced headache and dilated extracerebral arteries (>5â¯h) and slightly constricted MCA in healthy volunteers. Post hoc analysis of PACAP38 data compared with PACAP27 showed that PACAP isoforms dilates MMA with significantly different magnitude.
Assuntos
Circulação Cerebrovascular/efeitos dos fármacos , Cefaleia/fisiopatologia , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/efeitos adversos , Vasoconstrição/efeitos dos fármacos , Vasodilatação/efeitos dos fármacos , Adolescente , Adulto , Área Sob a Curva , Artérias Carótidas/diagnóstico por imagem , Artérias Carótidas/efeitos dos fármacos , Artérias Carótidas/fisiologia , Circulação Cerebrovascular/fisiologia , Método Duplo-Cego , Feminino , Cefaleia/induzido quimicamente , Cefaleia/diagnóstico por imagem , Voluntários Saudáveis , Humanos , Angiografia por Ressonância Magnética , Masculino , Artérias Meníngeas/diagnóstico por imagem , Artérias Meníngeas/efeitos dos fármacos , Artérias Meníngeas/fisiologia , Artéria Cerebral Média/diagnóstico por imagem , Artéria Cerebral Média/efeitos dos fármacos , Artéria Cerebral Média/fisiologia , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/administração & dosagem , Artérias Temporais/diagnóstico por imagem , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/fisiologia , Vasoconstrição/fisiologia , Vasodilatação/fisiologiaAssuntos
Arterite de Células Gigantes/diagnóstico , Aneurisma Intracraniano/diagnóstico , Doenças do Nervo Oculomotor/diagnóstico , Artérias Temporais/patologia , Idoso , Blefaroptose/diagnóstico , Proteína C-Reativa/metabolismo , Angiografia por Tomografia Computadorizada , Diplopia/diagnóstico , Feminino , Arterite de Células Gigantes/tratamento farmacológico , Glucocorticoides/administração & dosagem , Humanos , Aneurisma Intracraniano/tratamento farmacológico , Aneurisma Intracraniano/fisiopatologia , Prednisona/administração & dosagem , Artérias Temporais/efeitos dos fármacos , Acuidade VisualRESUMO
RATIONALE: Giant cell arteritis (GCA)-a primary vasculitis of medium and large arteries-is associated with vessel wall damage, elastic membrane fragmentation, and vascular remodeling. Proteinases are believed to contribute to pathogenesis by degrading extracellular matrix and causing tissue injury. OBJECTIVE: The MMP (matrix metalloproteinase)-9-a type IV collagenase-is produced in the vasculitic lesions of GCA. It is unknown which pathogenic processes are MMP-9 dependent. METHODS AND RESULTS: The tissue transcriptome of GCA-affected temporal arteries contained high amounts of MMP-9 transcripts, and immunostaining for pro-MMP-9 localized the enzyme to wall-infiltrating macrophages. MMP-2 and MMP-9 transcripts were also abundant in monocytes and monocyte-derived macrophages from patients with GCA. Patient-derived monocytes outperformed healthy monocytes in passing through engineered basement membranes. GCA CD (cluster of differentiation) 4+ T cells required MMP-9-producing monocytes to penetrate through matrix built from type IV collagen. In vivo functions of MMP-9 were tested in a human artery-SCID (severe combined immunodeficiency) chimera model by blocking enzyme activity with a highly specific monoclonal antibody or by injecting rMMP-9 (recombinant MMP-9). Inhibiting MMP-9 activity profoundly suppressed vascular injury, decreased the density of inflammatory infiltrates ( P<0.001), reduced intramural neoangiogenesis ( P<0.001), and prevented intimal layer hyperplasia ( P<0.001). rMMP-9 amplified all domains of vasculitic activity, promoted assembly of T-cell infiltrates ( P<0.05), intensified formation of new microvessels ( P<0.001), and worsened intimal thickening ( P<0.001). Systemic delivery of N-acetyl-proline-glycine-proline-a matrikine produced by MMP-9-mediated gelatinolysis-had limited vasculitogenic effects. CONCLUSIONS: In large vessel vasculitis, MMP-9 controls the access of monocytes and T cells to the vascular wall. T cells depend on MMP-9-producing monocytes to pass through collagen IV-containing basement membrane. Invasion of vasculitogenic T cells and monocytes, formation of neoangiogenic networks, and neointimal growth all require the enzymatic activity of MMP-9, identifying this protease as a potential therapeutic target to restore the immunoprivilege of the arterial wall in large vessel vasculitis.
Assuntos
Artéria Axilar/enzimologia , Linfócitos T CD4-Positivos/enzimologia , Movimento Celular , Arterite de Células Gigantes/enzimologia , Metaloproteinase 9 da Matriz/metabolismo , Monócitos/enzimologia , Artérias Temporais/enzimologia , Remodelação Vascular , Idoso , Idoso de 80 Anos ou mais , Animais , Anti-Inflamatórios/farmacologia , Anticorpos Monoclonais/farmacologia , Artéria Axilar/efeitos dos fármacos , Artéria Axilar/imunologia , Artéria Axilar/patologia , Membrana Basal/enzimologia , Membrana Basal/patologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/imunologia , Estudos de Casos e Controles , Movimento Celular/efeitos dos fármacos , Células Cultivadas , Feminino , Arterite de Células Gigantes/imunologia , Arterite de Células Gigantes/patologia , Arterite de Células Gigantes/prevenção & controle , Humanos , Masculino , Metaloproteinase 9 da Matriz/genética , Inibidores de Metaloproteinases de Matriz/farmacologia , Camundongos Endogâmicos NOD , Camundongos SCID , Pessoa de Meia-Idade , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Neointima , Neovascularização Patológica , Transdução de Sinais , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/imunologia , Artérias Temporais/patologia , Remodelação Vascular/efeitos dos fármacosRESUMO
Background: Giant-cell arteritis (GCA) is considered a T helper (Th)1- and Th17-mediated disease. Interleukin (IL)-12 is a heterodimeric cytokine (p35/p40) involved in Th1 differentiation. When combining with p19 subunit, p40 compose IL-23, a powerful pro-inflammatory cytokine that maintains Th17 response. Objectives: The aims of this study were to investigate p40, p35, and p19 subunit expression in GCA lesions and their combinations to conform different cytokines, to assess the effect of glucocorticoid treatment on subunit expression, and to explore functional roles of p40 by culturing temporal artery sections with a neutralizing anti-human IL-12/IL-23p40 antibody. Methods and results: p40 and p19 mRNA concentrations measured by real-time RT-PCR were significantly higher in temporal arteries from 50 patients compared to 20 controls (4.35 ± 4.06 vs 0.51 ± 0.75; p < 0.0001 and 20.32 ± 21.78 vs 4.17 ± 4.43 relative units; p < 0.0001, respectively). No differences were found in constitutively expressed p35 mRNA. Contrarily, p40 and p19 mRNAs were decreased in temporal arteries from 16 treated GCA patients vs those from 34 treatment-naïve GCA patients. Accordingly, dexamethasone reduced p40 and p19 expression in cultured arteries. Subunit associations to conform IL-12 and IL-23 were confirmed by proximity-ligation assay in GCA lesions. Immunofluorescence revealed widespread p19 and p35 expression by inflammatory cells, independent from p40. Blocking IL-12/IL-23p40 tended to reduce IFNγ and IL-17 mRNA production by cultured GCA arteries and tended to increase Th17 inducers IL-1ß and IL-6. Conclusion: IL-12 and IL-23 heterodimers are increased in GCA lesions and decrease with glucocorticoid treatment. p19 and p35 subunits are much more abundant than p40, indicating an independent role for these subunits or their potential association with alternative subunits. The modest effect of IL-12/IL-23p40 neutralization may indicate compensation by redundant cytokines or cytokines resulting from alternative combinations.
Assuntos
Arterite de Células Gigantes/imunologia , Subunidade p35 da Interleucina-12/genética , Subunidade p40 da Interleucina-12/genética , Subunidade p19 da Interleucina-23/genética , Células Th1/imunologia , Células Th17/imunologia , Idoso , Idoso de 80 Anos ou mais , Células Cultivadas , Citocinas , Feminino , Arterite de Células Gigantes/patologia , Glucocorticoides/uso terapêutico , Humanos , Subunidade p35 da Interleucina-12/imunologia , Subunidade p40 da Interleucina-12/imunologia , Subunidade p19 da Interleucina-23/imunologia , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/imunologia , Células Th1/efeitos dos fármacos , Células Th17/efeitos dos fármacosRESUMO
BACKGROUND: Giant cell arteritis, a chronic autoimmune disease of the aorta and its large branches, is complicated by aneurysm formation, dissection, and arterial occlusions. Arterial wall dendritic cells attract CD4+ T cells and macrophages to form prototypic granulomatous infiltrates. Vasculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering vasculitis. Transmural inflammation induces microvascular neoangiogenesis and results in lumen-occlusive intimal hyperplasia. We have examined whether persistent vessel wall inflammation is maintained by lesional T cells, including the newly identified tissue-resident memory T cells, and whether such T cells are sensitive to the cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1. METHODS: Vascular inflammation was induced in human arteries engrafted into immunodeficient mice that were reconstituted with T cells and monocytes from patients with giant cell arteritis. Mice carrying inflamed human arteries were treated with tofacitinib or vehicle. Vasculitic arteries were examined for gene expression (reverse transcription polymerase chain reaction), protein expression (immunohistochemistry), and infiltrating cell populations (flow cytometry). RESULTS: Tofacitinib effectively suppressed innate and adaptive immunity in the vessel wall. Lesional T cells responded to tofacitinib with reduced proliferation rates (<10%) and minimal production of the effector molecules interferon-γ, interleukin-17, and interleukin-21. Tofacitinib disrupted adventitial microvascular angiogenesis, reduced outgrowth of hyperplastic intima, and minimized CD4+CD103+ tissue-resident memory T cells. CONCLUSIONS: Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflammation of medium and large arteries. The JAK inhibitor tofacitinib effectively suppresses tissue-resident memory T cells and inhibits core vasculitogenic effector pathways.
Assuntos
Arterite de Células Gigantes/prevenção & controle , Inibidores de Janus Quinases/farmacologia , Janus Quinases/antagonistas & inibidores , Piperidinas/farmacologia , Pirimidinas/farmacologia , Pirróis/farmacologia , Fatores de Transcrição STAT/metabolismo , Linfócitos T/efeitos dos fármacos , Artérias Temporais/efeitos dos fármacos , Imunidade Adaptativa/efeitos dos fármacos , Transferência Adotiva , Idoso , Animais , Proliferação de Células/efeitos dos fármacos , Citocinas/imunologia , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Arterite de Células Gigantes/enzimologia , Arterite de Células Gigantes/imunologia , Arterite de Células Gigantes/patologia , Xenoenxertos , Humanos , Imunidade Inata/efeitos dos fármacos , Memória Imunológica/efeitos dos fármacos , Janus Quinase 1/antagonistas & inibidores , Janus Quinase 1/metabolismo , Janus Quinase 3/antagonistas & inibidores , Janus Quinase 3/metabolismo , Janus Quinases/metabolismo , Ativação Linfocitária/efeitos dos fármacos , Masculino , Camundongos Endogâmicos NOD , Camundongos SCID , Camundongos Transgênicos , Pessoa de Meia-Idade , Neointima , Neovascularização Patológica , Transdução de Sinais/efeitos dos fármacos , Linfócitos T/enzimologia , Linfócitos T/imunologia , Linfócitos T/transplante , Artérias Temporais/enzimologia , Artérias Temporais/imunologia , Artérias Temporais/transplante , Remodelação Vascular/efeitos dos fármacosRESUMO
Although clinical signs and symptoms of giant cell arteritis improve promptly after starting glucocorticoid therapy, reports have suggested that the vascular inflammation may persist. To assess the duration and quality of histopathologic changes in treated patients, we prospectively obtained second temporal artery biopsies in patients treated for 3 to 12 months after their first diagnostic biopsy. Forty patients (28 women, 12 men, median age 77 years) agreed to have a second temporal artery biopsy randomly assigned to 3, 6, 9, or 12 months subsequent to the first. Clinical and laboratory evaluation of the patient cohort revealed a typical rapid response and continued suppression of clinical manifestations as a result of glucocorticoid treatment. Histopathologic findings, evaluated in a blinded manner by a cardiovascular pathologist, showed unequivocal findings of vasculitis in 7/10 patients with second temporal artery biopsy at 3 months, 9/12 at 6 months, 4/9 at 9 months, and 4/9 at 12 months. Lymphocytes were present in all positive initial biopsies and remained the dominant cell population in chronically treated patients. Granulomatous inflammation decreased in a time-dependent manner from 78 to 100% at initial biopsy to 50% at 9 months and 25% at 12 months. The increased medial fibrosis noted in the second biopsies (60 vs 33% in primary temporal artery biopsies) suggested that the finding may represent a chronic finding in arteritis. In summary, the response to glucocorticoids in giant cell arteritis was frequently discordant. Clinical manifestations were readily suppressed, but vascular changes were gradual and often incomplete.
Assuntos
Arterite de Células Gigantes/tratamento farmacológico , Arterite de Células Gigantes/patologia , Glucocorticoides/uso terapêutico , Prednisona/uso terapêutico , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/patologia , Idoso , Idoso de 80 Anos ou mais , Biópsia , Feminino , Fibrose , Arterite de Células Gigantes/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Distribuição Aleatória , Artérias Temporais/imunologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Temporal arteritis peaks during the eighth decade, affecting patients with frequent comorbidities who are especially prone to adverse effects of corticosteroid therapy. Perivascular inflammation involving small periadventitial vessels is not uncommon in otherwise normal temporal artery biopsies (TABs). As ischemic events occur in patients with non-temporal artery--based inflammation, it has been recommended that any vascular inflammation within TABs be treated with corticosteroids. We sought to determine whether such patients are at increased risk for temporal arteritis-like adverse events compared with age-matched controls devoid of inflammatory infiltrates. TABs without transmural temporal arteritic damage accessioned between 2002 and 2012 were reviewed for inflammation (>15 perivascular lymphocytes) involving small blood vessels and/or temporal artery adventitia. Of 343 TABs, 278 (81%) were negative for transmural arteritis. Inflammation involving small vessels and/or temporal artery adventitia was present in 56 cases (20%). Age-matched controls were available for 39 cases. With a mean follow-up of 5 years (range, 1-11 years), 6/39 (15%) of patients developed stroke or cardiovascular events or died compared with 7/39 (18%) of age-matched controls. None of the patients with study-positive TAB had documented steroid therapy before or after TAB. Our results demonstrate that patients with inflammation involving only small vessels or temporal artery adventitia are not at increased risk for temporal arteritis-like adverse events, and suggest that the risks of protracted corticosteroid therapy in this elderly population likely exceed any potential benefits. We advise against diagnosing vasculitis in the absence of temporal arteritic damage.
Assuntos
Arterite de Células Gigantes/patologia , Inflamação/patologia , Artérias Temporais/patologia , Corticosteroides/efeitos adversos , Túnica Adventícia/patologia , Idoso , Idoso de 80 Anos ou mais , Biópsia , Estudos de Casos e Controles , Reações Falso-Positivas , Feminino , Arterite de Células Gigantes/tratamento farmacológico , Humanos , Inflamação/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Fatores de Risco , Artérias Temporais/efeitos dos fármacos , Fatores de TempoRESUMO
OBJECTIVES: To assess the detectability of vasculitic changes of the superficial cranial arteries with contrast-enhanced 7 T MRI in three patients with GCA and intraindividual comparison with 3 T MRI. METHODS: Three patients (two female, one male) with suspected GCA underwent contrast-enhanced T1-weighted high-resolution MRI at 3 T and 7 T magnetic field strength. The clinical diagnosis, based on criteria of the American College of Rheumatology, was confirmed by biopsy of the superficial temporal artery after MRI. MR images were visually assessed for detection of vasculitic mural contrast enhancement and vessel wall thickening of the superficial cranial arteries. RESULTS: Both 3 T and 7 T MRI allows for visualisation of mural inflammatory changes and assessment of the vasculitic involvement pattern. Image quality of 7 T MRI was rated superior to image quality of 3 T MRI scans. CONCLUSIONS: 7 T MR imaging of vasculitic changes in patients with GCA is possible, and suggests superior image quality. Larger patient studies are necessary to quantify the diagnostic advantages of 7 T MRI.
Assuntos
Arterite de Células Gigantes/diagnóstico por imagem , Imageamento por Ressonância Magnética , Artérias Temporais/diagnóstico por imagem , Idoso , Idoso de 80 Anos ou mais , Biópsia , Sedimentação Sanguínea , Estudos de Viabilidade , Feminino , Arterite de Células Gigantes/tratamento farmacológico , Arterite de Células Gigantes/patologia , Glucocorticoides/uso terapêutico , Humanos , Masculino , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/patologiaRESUMO
OBJECTIVE: Giant cell arteritis (GCA) is pathologically characterized by dysfunctional angiogenesis and inflammatory cell infiltration. Acute-phase serum amyloid A (A-SAA) is an acute-phase reactant, but is also produced at sites of inflammation and may contribute to vascular inflammation in atherosclerosis. This study was undertaken to examine the effect of A-SAA on proinflammatory pathways and angiogenesis in GCA, using a novel ex vivo temporal artery tissue explant model. METHODS: Serum A-SAA levels were measured by enzyme-linked immunosorbent assay (ELISA). Temporal artery explants and peripheral blood mononuclear cell (PBMC) cultures were established from patients with GCA. Temporal artery explant morphology, viability, and spontaneous release of proinflammatory mediators following 24-hour culture were assessed by hematoxylin and eosin, calcein viability staining, and ELISA. Temporal artery explants and PBMC cultures were stimulated with A-SAA (10 µg/ml), and interleukin-6 (IL-6), IL-8, vascular endothelial growth factor, Ang2, and matrix metalloproteinase 2 (MMP-2)/MMP-9 were quantified by ELISA and gelatin zymography. The effect of conditioned medium from temporal artery explants on angiogenesis was assessed using endothelial cell Matrigel tube-formation assays. Temporal artery explants were also embedded in Matrigel, and myofibroblast outgrowth was assessed. RESULTS: Serum A-SAA levels were significantly higher in GCA patients versus healthy controls (P < 0.0001). Intact tissue morphology, cell viability, and spontaneous cytokine secretion were demonstrated in temporal artery explants. A-SAA treatment induced a significant increase in the levels of IL-6 and IL-8 from temporal artery explants (P < 0.05) and IL-8 from PBMCs (P < 0.05) compared to basal conditions. Conditioned medium from A-SAA-treated explants significantly induced angiogenic tube formation (P < 0.05 versus basal controls). Finally, A-SAA induced myofibroblast outgrowth and MMP-9 activation. CONCLUSION: Our findings demonstrate a functional role for A-SAA in regulating temporal artery inflammation, angiogenesis, and invasion, all key processes in the pathogenesis of GCA.
Assuntos
Arterite de Células Gigantes/imunologia , Miofibroblastos/efeitos dos fármacos , Neovascularização Patológica/imunologia , Proteína Amiloide A Sérica/farmacologia , Artérias Temporais/efeitos dos fármacos , Proteínas de Fase Aguda/imunologia , Proteínas de Fase Aguda/farmacologia , Idoso , Idoso de 80 Anos ou mais , Células Cultivadas , Feminino , Arterite de Células Gigantes/metabolismo , Humanos , Técnicas In Vitro , Inflamação/imunologia , Interleucina-6/imunologia , Interleucina-8/efeitos dos fármacos , Interleucina-8/imunologia , Leucócitos Mononucleares , Masculino , Metaloproteinase 2 da Matriz/efeitos dos fármacos , Metaloproteinase 2 da Matriz/imunologia , Metaloproteinase 9 da Matriz/efeitos dos fármacos , Metaloproteinase 9 da Matriz/imunologia , Pessoa de Meia-Idade , Proteína Amiloide A Sérica/imunologia , Artérias Temporais/imunologia , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/imunologia , Proteínas de Transporte Vesicular/efeitos dos fármacos , Proteínas de Transporte Vesicular/imunologiaRESUMO
OBJECTIVE: Color duplex sonography (CDS) today is broadly used in the diagnostic workup of patients with suspected cranial or extracranial giant cell arteritis (GCA). This study aimed to determine the prognostic impact of the disease pattern assessed by CDS on the treatment response in GCA. METHODS: This was a retrospective, longitudinal follow-up study of 43 patients who were diagnosed with GCA at our institution between 2002 and 2010. All patients underwent CDS of the temporal and subclavian/axillary arteries at baseline and were observed for at least 6 months. Vasculitis was sonographically characterized by a circumferential, hypoechogenic wall thickening. According to the CDS findings, patients were categorized into patients with involvement of the subclavian/axillary arteries only (group A1, n = 17), patients with involvement of both the subclavian/axillary arteries and the temporal arteries (group A2, n = 9), and patients with isolated cranial GCA (group B, n = 17). Data on recurrences, corticosteroid doses, and steroid-sparing agents were extracted from the medical records. Treatment response over time was analyzed by Kaplan-Meier curves with log-rank testing. RESULTS: The mean follow-up time was 25.4 months and did not differ between groups (P = .4). Patients in group A1 were significantly younger than patients in groups A2 and B (P < .01). The interval between symptom onset and diagnosis was significantly longer in groups A1 and A2 compared with group B (P < .01). The number of recurrences per month was significantly higher in group A2 compared with group A1 and group B (A1, 0.07; A2, 0.13; B, 0.03; P < .01). Whereas there were no significant differences in the mean time until a daily prednisolone dose <10 mg was reached, patients in group A2 more frequently required steroid-sparing agents (A1, 24%; A2, 56%; B, 24%; P = .04). CONCLUSIONS: Extensive vascular involvement of both the temporal and subclavian/axillary arteries, as depicted by CDS, may be associated with a poor treatment response in GCA.
Assuntos
Corticosteroides/uso terapêutico , Artéria Axilar/efeitos dos fármacos , Artéria Axilar/diagnóstico por imagem , Artérias Carótidas/efeitos dos fármacos , Artérias Carótidas/diagnóstico por imagem , Arterite de Células Gigantes/diagnóstico por imagem , Arterite de Células Gigantes/tratamento farmacológico , Imunossupressores/uso terapêutico , Artéria Subclávia/efeitos dos fármacos , Artéria Subclávia/diagnóstico por imagem , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/diagnóstico por imagem , Ultrassonografia Doppler em Cores , Idoso , Estudos de Coortes , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Search for therapeutic targets in giant-cell arteritis (GCA) is hampered by the scarcity of functional systems. We developed a new model consisting of temporal artery culture in tri-dimensional matrix and assessed changes in biomarkers induced by glucocorticoid treatment. METHODS: Temporal artery sections from 28 patients with GCA and 22 controls were cultured in Matrigel for 5 days in the presence or the absence of dexamethasone. Tissue mRNA concentrations of pro-inflammatory mediators and vascular remodelling molecules was assessed by real-time RT-PCR. Soluble molecules were measured in the supernatant fluid by immunoassay. RESULTS: Histopathological features were exquisitely preserved in cultured arteries. mRNA concentrations of pro-inflammatory cytokines (particularly IL-1ß and IFNγ), chemokines (CCL3/MIP-1α, CCL4/MIP-1ß, CCL5/RANTES) and MMP-9 as well as IL-1ß and MMP-9 protein concentrations in the supernatants were significantly higher in cultured arteries from patients compared with control arteries. The culture system itself upregulated expression of cytokines and vascular remodelling factors in control arteries. This minimised differences between patients and controls but underlines the relevance of changes observed. Dexamethasone downregulated pro-inflammatory mediator (IL-1ß, IL-6, TNFα, IFNγ, MMP-9, TIMP-1, CCL3 and CXCL8) mRNAs but did not modify expression of vascular remodelling factors (platelet derived growth factor, MMP-2 and collagens I and III). CONCLUSIONS: Differences in gene expression in temporal arteries from patients and controls are preserved during temporal artery culture in tri-dimensional matrix. Changes in biomarkers elicited by glucocorticoid treatment satisfactorily parallel results obtained in vivo. This may be a suitable model to explore pathogenetic pathways and to perform preclinical studies with new therapeutic agents.
Assuntos
Biomarcadores/metabolismo , Avaliação Pré-Clínica de Medicamentos/métodos , Arterite de Células Gigantes/patologia , Glucocorticoides/farmacologia , Artérias Temporais/efeitos dos fármacos , Colágeno , Citocinas/biossíntese , Citocinas/genética , Dexametasona/farmacologia , Combinação de Medicamentos , Regulação da Expressão Gênica/efeitos dos fármacos , Arterite de Células Gigantes/metabolismo , Humanos , Mediadores da Inflamação/metabolismo , Laminina , Modelos Biológicos , Proteoglicanas , RNA Mensageiro/genética , Artérias Temporais/metabolismo , Artérias Temporais/patologia , Técnicas de Cultura de Tecidos/métodosRESUMO
BACKGROUND: Cerebral hyperperfusion (CHP) is a potential complication of superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis for moyamoya disease (MMD), and optimal postoperative management has not yet been established. Minocycline, a neuroprotective antibiotic agent, plays a role in blocking matrix metalloproteinase 9 (MMP-9), which contributes to edema formation and hemorrhagic conversion after cerebral ischemia-reperfusion. Patients with MMD have been shown to have increased serum MMP-9 levels. OBJECTIVE: To examine the effect of minocycline on the prevention of postoperative CHP after STA-MCA anastomosis for MMD. METHODS: N-isopropyl-p-[I]iodoamphetamine single-photon emission computed tomography was performed 1 and 7 days after STA-MCA anastomosis on 109 hemispheres in 86 consecutive patients with MMD (ages, 9-69 years; mean, 37.2 years). Postoperative systolic blood pressure was strictly maintained at lower than 130 mm Hg in all 109 surgeries. The most 60 recent hemispheres were managed by the intraoperative and postoperative intravenous administration of minocycline hydrochloride (200 mg/d). The incidence of focal neurological deterioration (FND) due to CHP was then compared with that in 36 patients undergoing 49 surgeries managed without minocycline. RESULTS: FND due to CHP was observed in 4 operated hemispheres in patients treated without minocycline (4/49, 8.16%), and in none in the minocycline-treated group (0/60) (P = .0241). Multivariate analysis revealed that minocycline administration (P < .001), surgery on the left hemisphere (P = .031), and a smaller recipient artery diameter (P < .001) significantly correlated with FND due to CHP. CONCLUSION: The administration of minocycline with strict blood pressure control may represent secure and effective postoperative management to prevent symptomatic CHP after STA-MCA anastomosis for MMD.
Assuntos
Revascularização Cerebral/efeitos adversos , Transtornos Cerebrovasculares/prevenção & controle , Minociclina/uso terapêutico , Doença de Moyamoya/cirurgia , Fármacos Neuroprotetores/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Traumatismo por Reperfusão/prevenção & controle , Adolescente , Adulto , Idoso , Anastomose Cirúrgica/efeitos adversos , Anastomose Cirúrgica/métodos , Determinação da Pressão Arterial , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Encéfalo/cirurgia , Revascularização Cerebral/métodos , Transtornos Cerebrovasculares/etiologia , Transtornos Cerebrovasculares/patologia , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Artéria Cerebral Média/efeitos dos fármacos , Artéria Cerebral Média/patologia , Artéria Cerebral Média/cirurgia , Minociclina/administração & dosagem , Fármacos Neuroprotetores/administração & dosagem , Cuidados Pós-Operatórios/métodos , Cintilografia , Traumatismo por Reperfusão/etiologia , Traumatismo por Reperfusão/patologia , Artérias Temporais/efeitos dos fármacos , Artérias Temporais/patologia , Artérias Temporais/cirurgia , Adulto JovemRESUMO
Temporal artery biopsy (TAB) is the diagnostic gold standard for giant cell arteritis (GCA). GCA is treated by high-dose corticosteroids. In cases of high clinical suspicion, steroids may be administrated despite negative TAB, making TAB clinically irrelevant. We assessed the role of TAB in clinical decision-making in patients with suspected GCA and to identify factors associated with clinically irrelevant TAB. Charts of patients who underwent TAB from 2005 to 2010 were reviewed for clinical parameters potentially associated with GCA and clinically irrelevant TAB. We studied 143 patients with 99 negative (69%), 34 positive (24%), and 10 undefined (7%) TABs. Eventually 26 patients (18% of the entire cohort and 26% of the patients with a negative TAB) received steroid treatment for GCA despite negative TAB. The start of steroid treatment before TAB was associated with clinically irrelevant TABs. If clinical suspicion of GCA is high, a TAB can be considered clinically irrelevant.